Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05255601
Title A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

Hodgkin's lymphoma

anaplastic large cell lymphoma

diffuse large B-cell lymphoma

primary mediastinal B-cell lymphoma

non-Hodgkin lymphoma

Therapies

Nivolumab + Relatlimab

Age Groups: adult | child
Covered Countries USA | ITA | FRA | ESP | DEU


No variant requirements are available.